Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis announces the availability of its management information circular for its upcoming annual general and special meeting of shareholders. The meeting will be held virtually on August 9, 2024, at 1:00 p.m. (Eastern time) / 11:00 a.m. (Mountain Time). Shareholders can access the circular on the company's website and SEDAR+. At the meeting, shareholders will vote on critical issues, including director nominees and meeting resolutions. Aurora emphasizes its recent financial stability and aims for positive free cash flow by the end of 2024. The company encourages shareholders to vote by August 7, 2024, and reach out to Laurel Hill Advisory Group for assistance.
Aurora Cannabis (NASDAQ: ACB) announced its FY2024 results, highlighting a record annual adjusted EBITDA of $12.8 million and a 21% increase in total net revenue compared to the previous fiscal year. In Q4 2024, the company achieved its sixth consecutive quarter of positive adjusted EBITDA, with total net revenue up 5% YoY to $67.4 million, driven by a 20% YoY growth in global medical cannabis revenue to $45.6 million. Aurora finished the fiscal year with approximately $180 million in cash and no cannabis-related debt. The company reaffirms its goal of achieving positive free cash flow by the end of 2024.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, announced that it will host a conference call to discuss its fourth quarter and fiscal year 2024 results. The call is scheduled for Thursday, June 20, 2024, at 8:00 a.m. Eastern Time. The financial results for the quarter will be released before the market opens on the same day. Miguel Martin, CEO, and Simona King, CFO, will lead the call and a subsequent Q&A session. The webcast link can be accessed on the company's investor information page.
Aurora Cannabis, a leading medical cannabis company, has announced the launch of its premium 1.2g resin cartridges in Australia in partnership with MedReleaf Australia. These new products are now available for doctors to prescribe and are manufactured in Aurora's EU-GMP and TGA-GMP certified facilities.
The resin cartridges come under the Aurora and IndiMed brands, offering high-quality, full-spectrum options like Sourdough and Electric Honeydew. The products are designed to ensure exceptional flavor, potency, safety, and ease of use.
This move marks a significant expansion for Aurora, aiming to enhance patient access to premium cannabis in the Australian market.
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) has appointed Rajesh Uttamchandani to its Board of Directors, effective May 15, 2024. Uttamchandani brings expertise in strategy development, innovation, human capital, and governance, with a background in senior roles at leading firms in technology, FinTech, and education sectors. His recent role was Chief People Officer at ApplyBoard, one of Canada's fastest-growing tech companies. Aurora's Chairman, Ron Funk, highlighted that Uttamchandani's experience aligns well with the company's strategic goals. Uttamchandani has served on boards of various organizations, including LifeSpeak and Ontario Cannabis Stores, and holds multiple advanced degrees and professional designations.
Aurora Cannabis Inc. marks the first shipment of medical cannabis products to the New Zealand market, showcasing premium, carefully crafted offerings. The company aims to redefine patient care by providing high-quality, potent products tailored to address various patient needs. The launch of these products signifies a significant milestone in improving medical cannabis accessibility in an emerging market like New Zealand.
Aurora Cannabis Inc. (ACB) and MedReleaf Australia have expanded their product offerings in Australia by introducing a new line of premium dried cannabis flower products. These products, including proprietary cultivars like Black Jelly, Chemango Kush, and Moon Berry, aim to provide patients with more choice and high-quality medical cannabis solutions. The expansion also includes the relaunch of the Vespera cultivar under the Aurora brand. The products are distributed by MedReleaf Australia, positioning itself as a leading distributor in the Australian market.
Summary not available.
Summary not available.
Summary not available.